|Application ||WB, IHC-P, IF|
|Dilution||IHC-P (5 µg/ml), WB (1-2 µg/ml),|
|Other Names||POU domain, class 3, transcription factor 2, Brain-specific homeobox/POU domain protein 2, Brain-2, Brn-2, Nervous system-specific octamer-binding transcription factor N-Oct-3, Octamer-binding protein 7, Oct-7, Octamer-binding transcription factor 7, OTF-7, POU3F2, BRN2, OCT7, OTF7|
|Target/Specificity||Human POU3F2. At least two isoforms are known to exist. This antibody will recognize both isoforms. POU3F2 antibody is predicted to not cross-react with other members of the POU domain class 3 family.|
|Reconstitution & Storage||Long term: -20°C; Short term: +4°C. Avoid repeat freeze-thaw cycles.|
|Precautions||BRN2 / POU3F2 Antibody (C-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Synonyms||BRN2, OCT7, OTF7|
|Function||Transcription factor that binds preferentially to the recognition sequence which consists of two distinct half-sites, ('GCAT') and ('TAAT'), separated by a nonconserved spacer region of 0, 2, or 3 nucleotides. Positively regulates the genes under the control of corticotropin-releasing hormone (CRH) and CRH II promoters (By similarity).|
|Tissue Location||Expressed specifically in the neuroectodermal cell lineage|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Transcription factor that binds preferentially to the recognition sequence which consists of two distinct half-sites, ('GCAT') and ('TAAT'), separated by a nonconserved spacer region of 0, 2, or 3 nucleotides. Positively regulates the genes under the control of corticotropin-releasing hormone (CRH) and CRH II promoters (By similarity).
Schreiber E.,et al.Nucleic Acids Res. 21:253-258(1993).
Angus J.,et al.Oncogene 11:691-700(1995).
Mungall A.J.,et al.Nature 425:805-811(2003).
He X.,et al.Nature 340:35-42(1989).
Waragai M.,et al.Hum. Mol. Genet. 8:977-987(1999).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.